His primary areas of study are Internal medicine, Immunology, Acquired immunodeficiency syndrome, Surgery and Cohort study. Peter Reiss regularly links together related areas like Gastroenterology in his Internal medicine studies. His work is dedicated to discovering how Immunology, Saquinavir are connected with Ritonavir and Pharmacotherapy and other disciplines.
His research in Acquired immunodeficiency syndrome intersects with topics in Absolute risk reduction, Epidemiology, Chemoprophylaxis, Adverse effect and Intensive care medicine. His research in the fields of Discontinuation and Asymptomatic overlaps with other disciplines such as Risk assessment. His Cohort study research is multidisciplinary, incorporating perspectives in Mortality rate and Viral load.
His main research concerns Internal medicine, Immunology, Acquired immunodeficiency syndrome, Cohort and Viral load. His research integrates issues of Gastroenterology and Surgery in his study of Internal medicine. He works mostly in the field of Gastroenterology, limiting it down to concerns involving Nevirapine and, occasionally, Efavirenz.
His work on Viral disease, Didanosine and Virus as part of general Immunology research is frequently linked to Cart, thereby connecting diverse disciplines of science. His work deals with themes such as Interquartile range, Incidence, Demography, Hepatitis C and Comorbidity, which intersect with Cohort. His biological study deals with issues like Regimen, which deal with fields such as Reverse-transcriptase inhibitor and Pharmacology.
His scientific interests lie mostly in Internal medicine, Cohort, Acquired immunodeficiency syndrome, Cohort study and Viral load. As part of his studies on Internal medicine, Peter Reiss often connects relevant areas like Poisson regression. The various areas that Peter Reiss examines in his Cohort study include Demography, Hepatitis C, Effects of sleep deprivation on cognitive performance, Coinfection and Comorbidity.
His Acquired immunodeficiency syndrome research is multidisciplinary, relying on both Transmission, Regimen, Absolute risk reduction and Cobra. His research in Cohort study tackles topics such as Odds ratio which are related to areas like Lopinavir. Viral load is a subfield of Immunology that he tackles.
Peter Reiss focuses on Internal medicine, Cohort, Acquired immunodeficiency syndrome, Cohort study and Comorbidity. His Internal medicine study incorporates themes from Cognition, Poisson regression and Men who have sex with men. His study in Cohort is interdisciplinary in nature, drawing from both Epidemiology and Biomarkers of aging.
Peter Reiss interconnects Immunodeficiency, Virology, Immunology and Cobra in the investigation of issues within Acquired immunodeficiency syndrome. His Cohort study research is multidisciplinary, incorporating perspectives in Relative risk, Regimen, Demography and Cause of death. His research integrates issues of Hepatitis B, Prospective cohort study, Adverse effect and Survival analysis in his study of Incidence.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Combination antiretroviral therapy and the risk of myocardial infarction
Nina Friis-Møller;Caroline A Sabin;Rainer Weber;Antonella d'Arminio Monforte.
The New England Journal of Medicine (2003)
Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel
Huldrych F Gunthard;Judith A Aberg;Joseph J Eron;Jennifer Frances Hoy.
Class of antiretroviral drugs and the risk of myocardial infarction.
Nina Friis-Moller;Peter Reiss;Caroline A. Sabin;Rainer Weber.
The New England Journal of Medicine (2007)
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Matthias Egger;Margaret May;Geneviève Chene;Andrew N. Phillips.
The Lancet (2002)
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
A Mocroft;B Ledergerber;C Katlama;O Kirk.
The Lancet (2003)
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study
Rainer Weber;Caroline A Sabin;Nina Friis-Møller;Peter Reiss.
JAMA Internal Medicine (2006)
Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study
Nina Friis-Møller;Rainer Weber;Peter Reiss;Rodolphe Thiebaut.
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
Caroline Sabin;Signe Westring Worm;Rainer Weber.
The Lancet (2008)
Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
Kees Brinkman;Jan A Smeitink;Johannes A Romijn;Peter Reiss.
The Lancet (1999)
A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients: The INCAS Trial
Julio S. G. Montaner;Peter Reiss;David Cooper;Stefano Vella.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: